| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q3 2023 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Zentalis Pharmaceuticals Inc. | 3 | Q2 2024 | 8.9% |
| Arcus Biosciences, Inc | 3 | Q2 2024 | 4.6% |
| Illumnia, Inc. | 3 | Q2 2024 | 3.5% |
| KRYSTAL BIOTECH INC | 3 | Q2 2024 | 3.7% |
| BeyondSpring Inc. | 3 | Q2 2024 | 3.6% |
| PHATHOM PHARMACEUTICALS INC | 3 | Q2 2024 | 2.7% |
| Equillium Inc. | 3 | Q2 2024 | 1.4% |
| Aura Biosciences, Inc. | 3 | Q2 2024 | 1.3% |
| GeneDx Holdings Corp. | 3 | Q2 2024 | 0.8% |
| AtriCure Inc. | 3 | Q2 2024 | 0.5% |
View Decheng Capital LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-04 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-14 |
| 13F-HR | 2024-02-12 |
View Decheng Capital LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.